سعر جريداموم مرهم 30 جرام 0.1% 2022

Mometasone furoate 0.1% topical ointment (30 g), a medium-potency topical corticosteroid; Egyptian product by Global Napi Pharmaceuticals.

• Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.Population: Patients 2 years of age or olderDailyMed (U.S. National Library of Medicine)

• Clinical trials: adverse reactions in 4.8% (burning, pruritus, skin atrophy, tingling/stinging, furunculosis); rosacea reported. Post-marketing (topical corticosteroids): irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, striae, miliaria; blurred vision, cataracts, glaucoma, raised intraocular pressure.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to mometasone furoate or to any component of the preparation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Systemic absorption can cause reversible HPA axis suppression with potential glucocorticosteroid insufficiency, Cushing's syndrome, hyperglycaemia and glucosuria; risk factors include large treatment areas, prolonged use, occlusion, altered skin barrier, liver failure and young age.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Paediatric patients may be more susceptible to systemic toxicity (larger skin surface to body mass ratio), including HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma; avoid contact with eyes and refer patients with visual symptoms to an ophthalmologist.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; decades of post-marketing and observational data have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal outcomes. Maternal use of potent or very potent topical corticosteroids may be associated with low birth weight; use on the smallest area for the shortest duration. Animal studies showed fetal malformations.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in milk after topical use; use on the smallest area for the shortest duration while breastfeeding and do not apply directly to the nipple and areola.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Mometasone furoate: Synthetic corticosteroid with anti-inflammatory, antipruritic and vasoconstrictive activity (US label).